OLMA
vs
S&P 500
OLMA
S&P 500
Over the past 12 months, OLMA has significantly outperformed S&P 500, delivering a return of +350% compared to the S&P 500's +12% growth.
Stocks Performance
OLMA vs S&P 500
Performance Gap
OLMA vs S&P 500
Performance By Year
OLMA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Olema Pharmaceuticals Inc
Glance View
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2020-11-19. The firm is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. The company is designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. The company is in the Phase I/ IIclinical trial, and in Phase I combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
